Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 7.6 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 3.8 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; glyceryl laurate; ethyl oleate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - acarbose -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - acarbose -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nifedipine -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - nimodipine, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; maize starch; crospovidone; magnesium stearate; hypromellose; macrogol 4000; iron oxide yellow; titanium dioxide - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus (eg hunt and hess grades i-iii).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, sugar coated - excipient ingredients: sucrose; macrogol 6000; povidone; lactose monohydrate; glycol montanate; maize starch; purified talc; calcium carbonate; magnesium stearate - for the control of conception.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 0.05 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: purified talc; glycol montanate; lactose monohydrate; povidone; magnesium stearate; sucrose; calcium carbonate; maize starch; macrogol 6000 - oral contraception.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 2 mg; ethinylestradiol, quantity: 35 microgram - tablet, sugar coated - excipient ingredients: povidone; calcium carbonate; maize starch; sucrose; lactose monohydrate; macrogol 6000; purified talc; magnesium stearate; glycol montanate - diane-35 ed is indicated for: the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree. diane-35 will also provide effective oral contraception in this patient group. it should not be used in combination with other hormonal contraceptives (see contraindications).,if the hirsutism has only recently appeared or has lately intensified to a considerable extent the cause (androgen-producing tumour or an adrenal-enzyme defect) must be clarified by differential diagnosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - lactobacillus rhamnosus, quantity: 2.8 billion cfu; lactobacillus acidophilus, quantity: 2.4 billion cfu; bifidobacterium animalis ssp lactis, quantity: 2.8 billion cfu - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; silicon dioxide; magnesium stearate; sodium ascorbate; sucrose; titanium dioxide; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - maintain/support intestinal health ; helps enhance/promote healthy digestive system function ; maintain/support digestive system health ; maintain/support intestinal good/beneficial/friendly flora ; helps restore good/beneficial/friendly intestinal/gut/bowel flora ; helps enhance/improve/promote/increase healthy digestive system flora/good bacteria growth ; helps enhance/improve/promote/increase intestinal good/beneficial/friendly bacteria growth ; maintain/support small intestine good/beneficial/friendly flora ; maintain/support immune system health ; enhance/improve/promote immune defence/immunity ; helps enhance/improve/promote immune system function ; maintain/support healthy immune system function ; helps stimulate a healthy immune system response ; enhance/improve/promote/increase nutrient uptake